Nuveen’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,425,282
| Closed | -$22.4M | – | 3458 |
|
|
2024
Q1 | $22.4M | Buy |
1,425,282
+12,483
| +0.9% | +$192K | 0.01% | 1115 |
|
|
2023
Q4 | $22.8M | Buy |
1,412,799
+98,194
| +7% | +$1.25M | 0.01% | 1063 |
|
|
2023
Q3 | $16.7M | Sell |
1,314,605
-39,960
| -3% | -$551K | 0.01% | 1142 |
|
|
2023
Q2 | $19.1M | Buy |
1,354,565
+33,549
| +3% | +$480K | 0.01% | 1096 |
|
|
2023
Q1 | $20.4M | Buy |
1,321,016
+450,516
| +52% | +$7.52M | 0.01% | 1032 |
|
|
2022
Q4 | $14.3M | Buy |
870,500
+56,851
| +7% | +$924K | 0.01% | 1264 |
|
|
2022
Q3 | $15.1M | Buy |
813,649
+669,851
| +466% | +$10.5M | 0.01% | 1207 |
|
|
2022
Q2 | $5.18M | Buy |
143,798
+17,045
| +13% | +$188K | ﹤0.01% | 1910 |
|
|
2022
Q1 | $4.56M | Buy |
126,753
+1,536
| +1% | +$13.1K | ﹤0.01% | 2110 |
|
|
2021
Q4 | $4.51M | Sell |
125,217
-19,462
| -13% | -$366K | ﹤0.01% | 2179 |
|
|
2021
Q3 | $4.77M | Sell |
144,679
-7,278
| -5% | -$232K | ﹤0.01% | 2240 |
|
|
2021
Q2 | $3.03M | Sell |
151,957
-9,607
| -6% | -$372K | ﹤0.01% | 2511 |
|
|
2021
Q1 | $3.22M | Sell |
161,564
-19,826
| -11% | -$923K | ﹤0.01% | 2383 |
|
|
2020
Q4 | $3.62M | Sell |
181,390
-403
| -0.2% | -$23.9K | ﹤0.01% | 2232 |
|
|
2020
Q3 | $3.63M | Sell |
181,793
-627
| -0.3% | -$30.7K | ﹤0.01% | 2090 |
|
|
2020
Q2 | $3.64M | Buy |
182,420
+77,103
| +73% | +$4.12M | ﹤0.01% | 2068 |
|
|
2020
Q1 | $4.34M | Sell |
105,317
-60,840
| -37% | -$3.38M | ﹤0.01% | 1793 |
|
|
2019
Q4 | $10.3M | Sell |
166,157
-136,104
| -45% | -$6.47M | ﹤0.01% | 1571 |
|
|
2019
Q3 | $10.3M | Buy |
302,261
+252,553
| +508% | +$7.48M | ﹤0.01% | 1553 |
|
|
2019
Q2 | $1.12M | Buy |
+49,708
| New | +$1.16M | ﹤0.01% | 2690 |
|
Other funds holding DCPH
Nuveen's DCPH Position: Q2 2024 in Review
Nuveen sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 1,425,282 shares — an estimated $22.4M sold.
Nuveen first reported a position in DCPH in Q2 2019 and held it in 20 quarters. The position peaked at $22.8M in Q4 2023. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Nuveen reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Nuveen sold 1,425,282 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $22.4M.
- Nuveen first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Nuveen's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $22.8M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.